Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Возможности габапентина в терапии болевой формы диабетической нейропатии
Возможности габапентина в терапии болевой формы диабетической нейропатии
Е.В.Бирюкова. Возможности габапентина в терапии болевой формы диабетической нейропатии. Consilium Medicum. Неврология (Прил.). 2014; 2: 15-18.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Harati Y. Diabetes and the nervous system. Endocrinol Metab Clin North Am 1996; 25 (2): 325–59.
2. Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol 2008; 21 (5): 527–33.
3. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54: 1615–25.
4. Said G. Diabetic Neuropathy. A Review. Nat Clin Pract Neurol 2007; 3 (6): 331–40.
5. Kempler P (ed.). Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
6. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Reviews 1999; 7: 245–52.
7. Данилов А. Б., Давыдов О. С. Нейропатическая боль. М.: Боргес, 2007.
8. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47 (2): 123–8.
9. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 2008; 9 (4): 301–14.
10. Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabet Med 1998; 15: 97–112.
11. DCCT: The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
12. EDIC: The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensivetherapy on microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002; 287: 2563–9.
13. Левин О. С. Лечение болевого синдрома при полиневропатиях. Трудный пациент. 2007; 4: 27–32.
14. Bril V, England J, Franklin GM et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. Prepublished online: April 11, 2011.
15. Wiffen PJ, Collins S, McQuay HJ et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews. 2005; 2: CD001133. DOI: 10.1002/14651858. CD001133.pub2. Available at: http://www.cochrane.org/reviews
16. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care 2008; 31: S255–61.
17. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25 (1): 81–104.
18. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000; 20 (4): 280–5.
19. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; CD007938 88.
20. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996; 12: 56–8.
21. Taylor CP, Gee NS, Su TZ et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 233–49.
22. Табеева ГР., Азимова ЮЭ. Фармакотерапия невропатической боли. Фармакотерапия. Фарматека. 2011; 9: 12–6.
23. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005; 94 (4): 1131–9.
2. Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol 2008; 21 (5): 527–33.
3. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54: 1615–25.
4. Said G. Diabetic Neuropathy. A Review. Nat Clin Pract Neurol 2007; 3 (6): 331–40.
5. Kempler P (ed.). Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
6. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Reviews 1999; 7: 245–52.
7. Данилов А. Б., Давыдов О. С. Нейропатическая боль. М.: Боргес, 2007.
8. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47 (2): 123–8.
9. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 2008; 9 (4): 301–14.
10. Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabet Med 1998; 15: 97–112.
11. DCCT: The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
12. EDIC: The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensivetherapy on microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002; 287: 2563–9.
13. Левин О. С. Лечение болевого синдрома при полиневропатиях. Трудный пациент. 2007; 4: 27–32.
14. Bril V, England J, Franklin GM et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. Prepublished online: April 11, 2011.
15. Wiffen PJ, Collins S, McQuay HJ et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews. 2005; 2: CD001133. DOI: 10.1002/14651858. CD001133.pub2. Available at: http://www.cochrane.org/reviews
16. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care 2008; 31: S255–61.
17. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25 (1): 81–104.
18. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000; 20 (4): 280–5.
19. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; CD007938 88.
20. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996; 12: 56–8.
21. Taylor CP, Gee NS, Su TZ et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 233–49.
22. Табеева ГР., Азимова ЮЭ. Фармакотерапия невропатической боли. Фармакотерапия. Фарматека. 2011; 9: 12–6.
23. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005; 94 (4): 1131–9.
Авторы
Е.В.Бирюкова
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.